Italia markets close in 1 hour 17 minutes
FTSE MIB
33.284,31 +376,26 (+1,14%) Dow Jones
38.798,55 +20,45 (+0,05%) Nasdaq
17.870,31 +13,29 (+0,07%) Nikkei 225
38.482,11 +379,67 (+1,00%) Petrolio
81,14 +0,81 (+1,01%) Bitcoin EUR
60.105,43 -680,38 (-1,12%)
NBIX Jul 2024 135.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:48PM EDT. Mercato aperto.
| Chiusura precedente | 5,90 |
| Aperto | 5,90 |
| Denaro | 3,70 |
| Domanda | 7,50 |
| Prezzo d'esercizio | 135,00 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 5,90 - 5,90 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 16 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.